Topicals & local formats · Contract manufacturing in India

Aloe Vera, Ketoconazole 1.0% w/v, Pyrithione 1.0% w/v, Salicylic Acid 2%, Zinc Soap

Request manufacturing feasibility

Discuss third-party manufacturing of Aloe Vera, Ketoconazole 1.0% w/v, Pyrithione 1.0% w/v, Salicylic Acid 2%, Zinc Soap with Walter Healthcare, India. Share your target market, required bar count and bar weight, packaging and launch timeline for a product-specific quotation.

Catalogue reference
WH-1768
Composition and strength
Aloe Vera, Ketoconazole 1.0% w/v, Pyrithione 1.0% w/v, Salicylic Acid 2%, Zinc
Dosage form
Soap
Indicative administration route
Topical
Therapeutic navigation area
Anti-infectives
Pharmacological class
Antifungal
Manufacturing stream
Non-beta-lactam

Catalogue details support an initial B2B discussion. Walter confirms the applicable unit, current licence scope, formula, target market and commercial feasibility before making a commitment.

Clinical reference

Mechanism and pharmacokinetics.

Explore the published evidence for the ingredients in Aloe Vera, Ketoconazole 1.0% w/v, Pyrithione 1.0% w/v, Salicylic Acid 2%, Zinc Soap. Each reference identifies its source formulation and study context. Ingredient studies describe the named reference product; they do not establish the pharmacokinetics, clinical suitability or bioequivalence of this finished formulation.

How to read our product information and sources ↗

Additional ingredient references still to be verified: Aloe Vera; Pyrithione; Zinc. The references below cover only the named ingredients.

Ingredient-level reference

Salicylic acid (ointment reference)

Reference for: Salicylic Acid. Source presentation: OINTMENT. Source route: topical.

Mechanism of action

Salicylic acid has a keratolytic action, supporting removal of excess keratin in the skin. The reference concerns a 2% ointment.

Pharmacokinetics

The reference acknowledges that salicylic acid can be absorbed through skin, while reporting no evidence of systemic absorption with this particular ointment. This product-specific statement is not a general claim of zero absorption: strength, vehicle, area treated and skin condition matter. Quantitative systemic exposure and half-life are not supplied for this formulation, and the statement does not establish absorption from a different combination.

Ingredient-level summary of the cited reference product. Study formulation, route, strength and population govern interpretation; these data do not establish pharmacokinetics or bioequivalence for Walter's formulation or fixed combination.

Source: Salicylic Acid Ointment BP 2%: SmPC, March 2025, sections 5.1–5.2

Reference accessed .

Prescribing-label excerpts

Ketoconazole

Reference for: Ketoconazole. Source presentation: shampoo. Source route: topical.

The source label presents its clinical-pharmacology findings together. These selected passages retain the source’s study context; the full label provides the complete discussion.

Clinical pharmacology

Tinea (pityriasis) versicolor is a non-contagious infection of the skin caused by Pityrosporum orbiculare (Malassezia furfur). This commensal organism is part of the normal skin flora. In susceptible individuals the condition is often recurrent and may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs. Treatment of the infection may not immediately result in restoration of pigment to the affected sites. Normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental skin exposure. The rate of recurrence of infection is variable.

Ketoconazole was not detected in plasma in 39 patients who shampooed 4-10 times per week for 6 months, or in 33 patients who shampooed 2-3 times per week for 3-26 months (mean: 16 months).

An exaggerated use washing test on the sensitive antecubital skin of 10 subjects twice daily for five consecutive days showed that the irritancy potential of ketoconazole shampoo, 2% was significantly less than that of 2.5% selenium sulfide shampoo.

A human sensitization test, a phototoxicity study, and a photoallergy study conducted in 38 male and 22 female volunteers showed no contact sensitization of the delayed hypersensitivity type, no phototoxicity and no photoallergenic potential due to ketoconazole shampoo, 2%.

Mode of Action: Interpretations of in vivo studies suggest that ketoconazole impairs the synthesis of ergosterol, which is a vital component of fungal cell membranes. It is postulated, but not proven, that the therapeutic effect of ketoconazole in tinea (pityriasis) versicolor is due to the reduction of Pityrosporum orbiculare (Malassezia furfur) and that the therapeutic effect in dandruff is due to the reduction of Pityrosporum ovale. Support for the therapeutic effect in tinea versicolor comes from a three-arm, parallel, double-blind, placebo controlled study in patients who had moderately severe tinea (pityriasis) versicolor. Successful response rates in the primary efficacy population for each of both three-day and single-day regimens of ketoconazole shampoo, 2% were statistically significantly greater (73% and 69%, respectively) than a placebo regimen (5%). There had been mycological confirmation of fungal disease in all cases at baseline. Mycological clearing rates were 84% and 78%, respectively, for the three-day and one-day regimens of the 2% shampoo and 11% in the placebo regimen. While the differences in the rates of successful response between either of the two active treatments and placebo were statistically significant, the difference between the two active regimens was not.

Microbiology: Ketoconazole is a broad spectrum synthetic antifungal agent which inhibits the growth of the following common dermatophytes and yeasts by altering the permeability of the cell membrane: dermatophytes: Trichophyton rubrum, T. mentagrophytes, T. tonsurans, Microsporum canis, M. audouini, M. gypseum and Epidermophyton floccosum; yeasts: Candida albicans, C. tropicalis, Pityrosporum ovale (Malassezia ovale) and Pityrosporum orbiculare (M. furfur). Development of resistance by these microorganisms to ketoconazole has not been reported.

Selected passages from the cited U.S. prescribing label. The studies concern the source product and populations named in each passage; they do not establish Walter-product bioequivalence, an approved indication, or the kinetics of another fixed combination. Tables and the full prescribing information remain available in the source.

Source: DailyMed: Ketoconazole — shampoo

Reference accessed . Label revision: 2026-01-29.

Editorial development perspective

What deserves attention in this formulation.

These notes use the catalogue composition and presentation to frame a technical discussion. They are planning considerations, not tested properties or clinical findings for this product.

The clinical references on this page cover only their named ingredients. These development notes do not resolve the remaining clinical-reference gaps.

About these development notes and source limitations ↗

Connect the active formula with the finished bar

Listed presentation: Soap.

Review ingredient distribution, bar consistency, weight control and compatibility with the chosen base. Define the finished-product classification and proposed claims before agreeing a development specification. Evaluate the actual wrapped product during storage; appearance at manufacture alone is not a basis for assigning its shelf life.

Define the botanical material precisely

Catalogue wording: “Aloe Vera”.

Identify the botanical source, plant part and whether the listed material is a powder, oil, extract or defined constituent. For an extract, request the extraction and standardisation details that distinguish the proposed grade. Use those details to compare suppliers; a shared plant name is not a complete material specification.

Translate the listed strength into a quantitative formula

Strength expressions in this entry include “1.0%”, “2%”.

Tie every stated ingredient amount to its intended dosage unit or measure, then distinguish that declared amount from the quantity of raw material needed for a batch. Record any assay or equivalence calculation in the formula. This gives development, purchasing and artwork teams the same strength definition without assigning a patient dose from the catalogue.

Suggested starting point

A practical starting point is to define the botanical material precisely. For this soap brief, agree the target characteristics and a short set of measurable development questions before comparing prototypes or supplier proposals. Keep unresolved clinical claims outside the product specification until supporting evidence is available.

Discuss this product brief

Manufacturing & packaging brief

Plan the soap presentation.

Use this preparation guide for Aloe Vera, Ketoconazole 1.0% w/v, Pyrithione 1.0% w/v, Salicylic Acid 2%, Zinc Soap. These are the decisions to resolve with the technical team before a site, process and commercial scope are confirmed.

Presentation & formulation

State the complete formula, active concentration, bar weight and proposed product claims. Confirm the product classification and relevant manufacturing scope for the market.

Quality & technical transfer

Agree the applicable chemical, physical and microbiological specifications and the evidence required for proposed label claims.

Review the technical documents

Packaging configuration

Describe the bar wrap, carton, pack count and artwork. Review contact materials and the proposed shelf-life basis with the technical team.

Explore packaging options

Details to confirm for this record

Full composition
Keep all named components and their individual amounts together in the specification. Ingredient substitutions, omissions and changed ratios require a separate formula and permission review.

Quantities, MOQ & lead time

For Aloe Vera, Ketoconazole 1.0% w/v, Pyrithione 1.0% w/v, Salicylic Acid 2%, Zinc Soap, state the bar count and bar weight, target market and reorder forecast. MOQ and lead time depend on the assessed formula, process, components, testing and project readiness; request those terms in writing.

Discuss this manufacturing brief

Explore the context

Build the right manufacturing brief.

Common questions

Before you request a quotation.

Aloe Vera, Ketoconazole 1.0% w/v, Pyrithione 1.0% w/v, Salicylic Acid 2%, Zinc Soap

What is listed in the catalogue?

The catalogue lists Aloe Vera, Ketoconazole 1.0% w/v, Pyrithione 1.0% w/v, Salicylic Acid 2%, Zinc as soap in its anti-infectives navigation area and non-beta-lactam manufacturing stream.

How do you confirm manufacturing availability?

Send Walter your requirement for Aloe Vera, Ketoconazole 1.0% w/v, Pyrithione 1.0% w/v, Salicylic Acid 2%, Zinc Soap. The team reviews the applicable product permission and unit, formulation and equipment fit, testing, packaging and production schedule before confirming the manufacturing scope in writing. Request the relevant product and facility documents with your enquiry.

What do I need for a quotation?

Share the exact composition and strength, soap presentation, target market, initial quantity, preferred pack and timing. Identify whether this is a new product, development brief or transfer.

The quotation must confirm MOQ, inclusions, prerequisites and lead time for the proposed product and site.

What is needed for Indian and export markets?

For India, share the intended brand or institutional supply requirement, pack sizes, initial order quantity and artwork needs for Aloe Vera, Ketoconazole 1.0% w/v, Pyrithione 1.0% w/v, Salicylic Acid 2%, Zinc Soap. Confirm the applicable product permission, manufacturing unit and labelling requirements with the team.

For export, identify each destination country, proposed pack, language and registration or dossier requirements. Ask which product-specific quality and stability documents are available. Container compatibility and destination-market requirements need review; a catalogue record does not establish export registration or a shelf-life commitment.

How do I submit my enquiry?

Use the product-specific enquiry button to carry this composition and dosage form into the form. After a successful submission, a receipt reference confirms that your brief has been saved for review. Use the RFQ checklist to prepare the remaining details.

Technical document review

Which documents can I ask Walter to review?

Ask about manufacturing and packing records, specifications, analytical methods, Certificates of Analysis (COA), stability evidence, the Process Validation Protocol (PVP) and Process Validation Report (PVR). The wider checklist below covers supplier qualification, technical transfer and ongoing supply.

View the full document checklist 14 review areas
Site, licence and audit scope
Manufacturing licence, applicable product permissions, GMP certificates, Site Master File, supplier-qualification questionnaire and relevant audit responses.
Manufacturing, packing and batch release
Master Formula Record (MFR), master packing instructions, Batch Manufacturing Record (BMR), Batch Packing Record (BPR), reconciliation and authorised release records.
Process validation and continued verification
Process Validation Protocol (PVP), Process Validation Report (PVR), process performance qualification documents and continued process verification trends.
Equipment, facilities and utilities
Validation Master Plan (VMP), user requirements, DQ/IQ/OQ/PQ records, calibration and maintenance evidence for relevant equipment and utilities.
Cleaning, carryover and hold times
Cleaning Validation Protocol (CVP), Cleaning Validation Report (CVR), residue limits, recovery studies and applicable clean, dirty and process hold-time studies.
Specifications and analytical evidence
Specifications, Method of Analysis (MOA), Standard Testing Procedure (STP), Certificates of Analysis (COA), analytical validation, verification and method-transfer records.
Stability, packaging and transport
Stability protocols/reports, ongoing stability commitments, pack specifications, approved artwork, compatibility and applicable packaging or transport studies.
Development and technology transfer
Development report, technology-transfer protocol/report, gap assessment, control strategy, critical quality attributes and critical process parameters.
Quality reviews, investigations and changes
Product Quality Review (PQR) / Annual Product Review (APR), deviations, CAPA, change control, OOS/OOT trends, complaints, recalls and relevant SOP/training records.
Material suppliers and impurity risks
API/excipient supplier qualification, traceability, material COAs, relevant origin declarations and impurity risk assessments with supporting tests.
Sterile-product evidence, where applicable
Contamination Control Strategy (CCS), media-fill/aseptic simulation reports, sterilisation and filtration validation, environmental monitoring, sterility/endotoxin and container-closure integrity evidence.
Computerised systems and data integrity
Computerised-system validation, access controls, audit-trail review, backup/restore checks and relevant data-integrity procedures.
Market-specific regulatory support
Applicable dossier sections, API master-file/CEP support, bioequivalence or biowaiver evidence and Certificate of a Pharmaceutical Product (CPP/CoPP), where required and available.
Quality agreement and access arrangements
Quality/technical agreement covering responsibilities, release, changes, subcontracting, investigations, complaints, recalls, audits and document access.

Agree the list for the exact product, site, process, pack, market and project stage. QA confirms what exists, applies and may be shared; some records may require an NDA, redaction or controlled review. See document definitions and review guidance.

Important qualification

This B2B catalogue record is not proof of current approval or confirmation that Aloe Vera, Ketoconazole 1.0% w/v, Pyrithione 1.0% w/v, Salicylic Acid 2%, Zinc Soap is available for sale. It is not prescribing information or patient advice. Any Drugs Rules status, current approval, exemption, applicable unit, licence scope, formulation, claims, brand use, destination-market registration and commercial feasibility require documentary verification and Walter's written confirmation. Read the full regulatory disclaimer.

Composition and classification are taken from Walter's product catalogue. The manufacturing guide helps buyers prepare a technical brief. Clinical references, where shown, describe the cited product and study. Manufacturing guide updated .